MedTrace Logo

Steady-state Pharmacokinetics of Ceftazidime/Avibactam in Cystic Fibrosis

NCT02504827 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2018-11-27

Study results available
· View outcomes & findings →

Summary

The purpose of this research study is to characterize the pharmacokinetics of intravenous ceftazidime/avibactam in patients with Cystic Fibrosis.

Conditions

Interventions

DRUG

Ceftazidime/avibactam

Ceftazidime/avibactam 2.5gm iv q8h for 3 doses

Sponsors & Collaborators

  • University of Southern California

    lead OTHER

Principal Investigators

  • Paul Beringer, PharmD · University of Southern California

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-09-30
Primary Completion
2016-10-31
Completion
2016-10-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02504827 on ClinicalTrials.gov